Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Status:
Completed
Trial end date:
2017-03-30
Target enrollment:
Participant gender:
Summary
There is no accepted standard chemotherapy approved for use in the second line for patients
with advanced urothelial carcinoma whose cancer has progressed on combination chemotherapy
including either cisplatin or carboplatin. The chemotherapy class called taxanes, either as
single agents or in combination, have demonstrated modest efficacy in small studies.
Cabazitaxel is an agent in the taxane family designed to be active in the setting of acquired
multi-drug resistance that arises in some tumors. The objective of this study is to evaluate
the safety and efficacy of this agent in patients with urothelial carcinoma refractory
compared to combination platinum based chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University